uniQure N.V. (QURE)
| Market Cap | 805.90M |
| Revenue (ttm) | 20.20M |
| Net Income (ttm) | -217.58M |
| Shares Out | 54.75M |
| EPS (ttm) | -4.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,317 |
| Open | 14.81 |
| Previous Close | 14.88 |
| Day's Range | 14.72 - 14.81 |
| 52-Week Range | 4.45 - 19.18 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 37.20 (+152.72%) |
| Earnings Date | Jul 31, 2025 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price target is $37.2, which is an increase of 152.72% from the latest price.
News
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough T...
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director, Investor Relations Matt Kapusta - Chief Executive Officer Walid...
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related...
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phas...
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volat...
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operat...
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential B...
uniQure N.V.: A Potential Huntington's Play
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's ...
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dez...
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal level...
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
Final Trade: DVN, QURE, GOOGL, DFH
The final trades of the day with the Fast Money traders.
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Applica...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~